section name header

General Information ⬇

Class Name(s):

Pronunciation:

Brand Name(s):

Use ⬆ ⬇

WHY is this medicine prescribed?

Piflufolastat F-18 is used to identify lesions (spots) of prostate cancer in those people undergoing a positron emission tomography (PET) scan. Piflufolastat F-18 is in a class of medications called radioactive diagnostics. It works by binding to cells that contain prostate-specific membrane antigen (PSMA) that is found in increased amounts in prostate cancer cells.

HOW should this medicine be used?

Piflufolastat F-18 comes as a solution to give intravenously. Specially trained healthcare professionals will give it about an hour before the PET scan.

Drink water to hydrate before the procedure as directed by your healthcare provider. To reduce the amount of radiation exposure from the medication, continue to drink water and urinate frequently for the first few hours after the procedure.

Ask your pharmacist or doctor for a copy of the manufacturer's information for the patient.

Are there OTHER USES for this medication?

This medication may be prescribed for other uses; ask your doctor or pharmacist for more information.

Special ⬆ ⬇

What SPECIAL PRECAUTIONS should I follow?

Before receiving piflufolastat F-18,

What SPECIAL DIETARY instructions should I follow?

Unless your doctor tells you otherwise, continue your normal diet.

Side Effects ⬆ ⬇

What SIDE EFFECTS can this medicine cause?

Piflufolastat F-18 may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:

Some side effects can be serious. If you experience any of these symptoms call your doctor immediately or get emergency medical treatment:

Piflufolastat F-18 may cause an increase chance of cancer due to radiation exposure. Talk to your doctor about the risks of taking this medication.

Piflufolastat F-18 may cause other side effects. Call your doctor if you have any unusual problems while taking this medication.

If you experience a serious side effect, you or your doctor may send a report to the Food and Drug Administration's (FDA) MedWatch Adverse Event Reporting program online (http://www.fda.gov/Safety/MedWatch) or by phone (1-800-332-1088).

Miscellaneous ⬆

What OTHER INFORMATION should I know?

Keep all appointments with your doctor.

Keep a written list of all of the prescription and nonprescription (over-the-counter) medicines, vitamins, minerals, and dietary supplements you are taking. Bring this list with you each time you visit a doctor or if you are admitted to the hospital. You should carry the list with you in case of emergencies.

This report on medications is for your information only, and is not considered individual patient advice. Because of the changing nature of drug information, please consult your physician or pharmacist about specific clinical use.

The American Society of Health-System Pharmacists, Inc. represents that the information provided hereunder was formulated with a reasonable standard of care, and in conformity with professional standards in the field. The American Society of Health-System Pharmacists, Inc. makes no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information and specifically disclaims all such warranties. Users are advised that decisions regarding drug therapy are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and the information is provided for informational purposes only. The entire monograph for a drug should be reviewed for a thorough understanding of the drug's actions, uses and side effects. The American Society of Health-System Pharmacists, Inc. does not endorse or recommend the use of any drug. The information is not a substitute for medical care.

AHFS® Patient Medication Information™ Copyright, 2026. The American Society of Health-System Pharmacists®, 4500 East-West Highway, Suite 900, Bethesda, Maryland. All Rights Reserved. Duplication for commercial use must be authorized by ASHP.

Selected Revisions: May 15, 2026.